Author: Tilg, Herbert

Source: Expert Opinion on Therapeutic Targets, Volume 11, Number 6, June 2007 , pp. 853-856(4)

Publisher: Informa Healthcare

Abstract:

Inflammatory bowel diseases affect > 1 million Europeans, and mostly people at a young age. Although these diseases are still increasing worldwide, especially in children and adolescents, progress in the pathophysiology and treatment of these diseases in recent years has been tremendous. In particular, anti-TNF-α agents dramatically changed the management of these diseases. The European Crohn's Colitis Organization recently held its second annual meeting in Innsbruck, Austria dealing with both new basic and clinical developments in the field.

Keywords: anti-TNF agent; Crohn's disease; TNF-α; ulcerative colitis

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14728222.11.6.853

Publication date: 2007-06-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Tilg, Herbert

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers